Smith & Nephew SNATS (NYSE:SNN) Price Target Raised to $35.00

Smith & Nephew SNATS (NYSE:SNN) had its price objective raised by Canaccord Genuity Group from $34.00 to $35.00 in a research note published on Thursday,Benzinga reports. Canaccord Genuity Group currently has a hold rating on the medical equipment provider’s stock.

Other research analysts have also recently issued research reports about the company. Royal Bank Of Canada cut Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research note on Monday, December 15th. Kepler Capital Markets upgraded Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday, November 17th. Wall Street Zen lowered Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $36.25.

Smith & Nephew SNATS Price Performance

Smith & Nephew SNATS stock opened at $34.29 on Thursday. Smith & Nephew SNATS has a fifty-two week low of $23.91 and a fifty-two week high of $38.79. The stock’s 50 day simple moving average is $34.43 and its two-hundred day simple moving average is $34.92. The company has a quick ratio of 1.40, a current ratio of 2.57 and a debt-to-equity ratio of 0.60.

Smith & Nephew SNATS Dividend Announcement

The firm also recently announced a dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Friday, March 27th will be issued a dividend of $0.482 per share. This represents a dividend yield of 281.0%. The ex-dividend date is Friday, March 27th.

Institutional Trading of Smith & Nephew SNATS

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada raised its stake in Smith & Nephew SNATS by 16.7% during the first quarter. Royal Bank of Canada now owns 340,428 shares of the medical equipment provider’s stock valued at $9,657,000 after buying an additional 48,784 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Smith & Nephew SNATS by 49.2% in the first quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock worth $50,255,000 after acquiring an additional 583,809 shares during the last quarter. Focus Partners Wealth grew its stake in shares of Smith & Nephew SNATS by 59.8% in the first quarter. Focus Partners Wealth now owns 19,438 shares of the medical equipment provider’s stock worth $552,000 after acquiring an additional 7,277 shares during the last quarter. Atria Investments Inc increased its holdings in shares of Smith & Nephew SNATS by 12.8% during the second quarter. Atria Investments Inc now owns 22,327 shares of the medical equipment provider’s stock valued at $684,000 after acquiring an additional 2,527 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC increased its holdings in shares of Smith & Nephew SNATS by 197.1% during the second quarter. Campbell & CO Investment Adviser LLC now owns 46,086 shares of the medical equipment provider’s stock valued at $1,412,000 after acquiring an additional 30,574 shares in the last quarter. Hedge funds and other institutional investors own 25.64% of the company’s stock.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.